Protalix BioTherapeutics Q1 revenue up 170% to $10.0M, net loss narrows to $3.6M

Protalix BioTherapeutics, Inc.

2025-Q1 EPS reported -$0.05 revenue$10,113,000

Revenues from selling goods $10.0M, up 170% YoY, driven by $5.9M increase in sales to Pfizer.
Net loss $3.6M ($0.05/sh) vs $4.6M ($0.06/sh) in Q1 2024; cash $34.7M.
Phase II trial of gout candidate PRX-115 expected to start H2 2025 after positive FIH results.
R&D expenses $3.5M (+21% YoY) due to clinical pipeline advancement; SG&A down 16% to $2.6M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.